Thank you for Subscribing to Life Science Review Weekly Brief
Opportunities across products, transforming how chronic illnesses are treated, and favorable government regulations drive today's market.
FREMONT, CA: The pharmaceutical and packaging sectors in many ways have a symbiotic relationship, each spurring and inspiring innovations of the other, in addition to being heavily influenced by external factors. There is also an increase in interest in flexible fillers and packaging components for biologics. This technology lends itself well to biologic production in multiple format presentations. If a pharma firm can switch nimbly to a flexible filler, they can accelerate production space, have higher utilization on capital equipment, and generate high-quality, small batches. Here is how packaging requirements for pharmaceuticals are changing.
Commitment to the secure and most efficient packaging and delivery of drug products needs a detailed understanding of the continually changing regulatory landscape. The pharmaceutical and packaging sectors have to constantly evolve to adhere to stricter guidelines of excellence and do so under increased scrutiny. The United States Pharmacopeia (USP) also continuously generates and revises standards in response to industry requirements to keep up with the evolving pharmaceutical sector.
Specific to packaging, in the last few years, there has been a rise in revisions of USP chapters based on the evaluation of packaging components for drug products.
These transformations can be a lot to keep up with. There is the opportunity for firms to offer expertise as a partner to pharmaceutical firms, ensuring drugs are packaged and offered following the regulations. This is possible through expertise and optimal facility to help customers and having the potentials to design and perform studies to demonstrate compliance throughout a product's lifecycle.
As market trends continue to evolve, so must packaging. As yesterday's efforts continue to inform the paths today and tomorrow, the global pandemic's eruption will likely alter the shape of the industry moving forward in ways people might not have fathomed. Treatment regimens will continue to shift toward shorter or less frequent dosing and more self-administered choices. Particularly as people stay home and reduce non-emergency doctor or hospital visits, the requirement for new packaging and delivery systems that enable patients to get treatment in the comfort of their home is to increase even faster.